Compare MOH & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOH | RDY |
|---|---|---|
| Founded | 1980 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 11.8B |
| IPO Year | 2002 | 2001 |
| Metric | MOH | RDY |
|---|---|---|
| Price | $223.27 | $12.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 1 |
| Target Price | ★ $167.00 | $16.90 |
| AVG Volume (30 Days) | 884.9K | ★ 3.0M |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $45,426,000,000.00 | N/A |
| Revenue This Year | $2.40 | $7.72 |
| Revenue Next Year | $5.18 | $3.50 |
| P/E Ratio | $837.20 | ★ $18.67 |
| Revenue Growth | ★ 11.75 | N/A |
| 52 Week Low | $121.06 | $12.19 |
| 52 Week High | $244.89 | $15.67 |
| Indicator | MOH | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 54.49 | 34.89 |
| Support Level | $175.18 | $12.19 |
| Resistance Level | N/A | $13.96 |
| Average True Range (ATR) | 9.45 | 0.37 |
| MACD | -1.64 | -0.22 |
| Stochastic Oscillator | 16.88 | 2.35 |
Molina Healthcare Inc provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. The company operates in four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in four states-California, New York, Texas, and Washington-account for over half of its enrollees.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.